Doug Long, BA, MBA, vice president of Industry Relations at IQVIA, shares what's happening in the growing GLP-1 and biosimilars space. Long was a presenter at the annual AMCP 2025 meeting in Houston, ...

The study explores whether Prolia/Xgeva (denosumab), a widely used therapy for osteoporosis and bone tumors, can regenerate ...

Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their ...

Maria Lowe, Ph.D., associate vice president of Pharmaceutical Intelligence at Institute for Clinical and Economic Review ...